<?xml version='1.0' encoding='utf-8'?>
<document id="18691987"><sentence text="Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study."><entity charOffset="20-32" id="DDI-PubMed.18691987.s1.e0" text="rosuvastatin" /><entity charOffset="58-68" id="DDI-PubMed.18691987.s1.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.18691987.s1.e0" e2="DDI-PubMed.18691987.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18691987.s1.e0" e2="DDI-PubMed.18691987.s1.e1" /></sentence><sentence text="Rifampicin (rifampin) has been reported to have drug-drug interaction with several 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors due to its ability to influence the function of cytochrome P450 enzymes or transporters"><entity charOffset="0-10" id="DDI-PubMed.18691987.s2.e0" text="Rifampicin" /><entity charOffset="12-20" id="DDI-PubMed.18691987.s2.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.18691987.s2.e0" e2="DDI-PubMed.18691987.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18691987.s2.e0" e2="DDI-PubMed.18691987.s2.e1" /></sentence><sentence text=" Rosuvastatin is absorbed from the blood into the liver by organic anion transporting polypeptide 1B1 and is then metabolized by cytochrome P450 isozyme 2C9"><entity charOffset="1-13" id="DDI-PubMed.18691987.s3.e0" text="Rosuvastatin" /></sentence><sentence text="" /><sentence text="The aim of this study was to examine the effect of rifampicin on the pharmacokinetics of rosuvastatin"><entity charOffset="51-61" id="DDI-PubMed.18691987.s5.e0" text="rifampicin" /><entity charOffset="89-101" id="DDI-PubMed.18691987.s5.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.18691987.s5.e0" e2="DDI-PubMed.18691987.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18691987.s5.e0" e2="DDI-PubMed.18691987.s5.e1" /></sentence><sentence text="" /><sentence text="This was a randomized, single-blind, placebo-controlled, crossover study, with a 4-week washout period" /><sentence text=" Healthy male volunteers were treated for 6 days with rifampicin 450 mg or placebo once daily"><entity charOffset="54-64" id="DDI-PubMed.18691987.s8.e0" text="rifampicin" /></sentence><sentence text=" On days 0 and 7, a single oral dose of rosuvastatin 20 mg was administered"><entity charOffset="40-52" id="DDI-PubMed.18691987.s9.e0" text="rosuvastatin" /></sentence><sentence text=" Plasma concentrations of rosuvastatin were measured by liquid chromatography-tandem mass spectrometry"><entity charOffset="26-38" id="DDI-PubMed.18691987.s10.e0" text="rosuvastatin" /></sentence><sentence text="" /><sentence text="A total of 18 healthy Chinese male volunteers (mean [SD] age, 21 [2] years; weight, 62 [7] kg; and body mass index was within the normal range [22" /><sentence text="0-24" /><sentence text="0 kg/m2]) were included in the study" /><sentence text=" The plasma concentrations of rosuvastatin were not significantly changed by pretreatment with rifampicin, although there was considerable interindividual variation in the plasma concentration of rosuvastatin"><entity charOffset="30-42" id="DDI-PubMed.18691987.s15.e0" text="rosuvastatin" /><entity charOffset="95-105" id="DDI-PubMed.18691987.s15.e1" text="rifampicin" /><entity charOffset="196-208" id="DDI-PubMed.18691987.s15.e2" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.18691987.s15.e0" e2="DDI-PubMed.18691987.s15.e0" /><pair ddi="false" e1="DDI-PubMed.18691987.s15.e0" e2="DDI-PubMed.18691987.s15.e1" /><pair ddi="false" e1="DDI-PubMed.18691987.s15.e0" e2="DDI-PubMed.18691987.s15.e2" /><pair ddi="false" e1="DDI-PubMed.18691987.s15.e1" e2="DDI-PubMed.18691987.s15.e1" /><pair ddi="false" e1="DDI-PubMed.18691987.s15.e1" e2="DDI-PubMed.18691987.s15.e2" /></sentence><sentence text=" During the rifampicin phase, the AUC(0-infinity) of rosuvastatin decreased in 10 and increased in 8 of the 18 subjects"><entity charOffset="12-22" id="DDI-PubMed.18691987.s16.e0" text="rifampicin" /><entity charOffset="53-65" id="DDI-PubMed.18691987.s16.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.18691987.s16.e0" e2="DDI-PubMed.18691987.s16.e0" /><pair ddi="false" e1="DDI-PubMed.18691987.s16.e0" e2="DDI-PubMed.18691987.s16.e1" /></sentence><sentence text=" In 3 of the 8 subjects, the AUC(0-infinity) of rosuvastatin during the rifampicin phase was &gt; or = 50% compared with the placebo phase; and only 1 increased by more than double (183%)"><entity charOffset="48-60" id="DDI-PubMed.18691987.s17.e0" text="rosuvastatin" /><entity charOffset="72-82" id="DDI-PubMed.18691987.s17.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.18691987.s17.e0" e2="DDI-PubMed.18691987.s17.e0" /><pair ddi="false" e1="DDI-PubMed.18691987.s17.e0" e2="DDI-PubMed.18691987.s17.e1" /></sentence><sentence text=" Of those in the decreased group (n = 10), the AUC(0-infinity) values were decreased by &gt;50% in 3 subjects and were not decreased by &gt;30% in the remaining 7 subjects" /><sentence text=" The mean AUC(0-infinity) of rosuvastatin was 95"><entity charOffset="29-41" id="DDI-PubMed.18691987.s19.e0" text="rosuvastatin" /></sentence><sentence text="8% (110" /><sentence text="4 [41" /><sentence text="4] vs 115" /><sentence text="3 [30" /><sentence text="9] ng/mL " /><sentence text=" h(-1)) of the corresponding value during the placebo phase (P = NS)" /><sentence text=" There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18"><entity charOffset="81-93" id="DDI-PubMed.18691987.s26.e0" text="rosuvastatin" /><entity charOffset="106-116" id="DDI-PubMed.18691987.s26.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.18691987.s26.e0" e2="DDI-PubMed.18691987.s26.e0" /><pair ddi="false" e1="DDI-PubMed.18691987.s26.e0" e2="DDI-PubMed.18691987.s26.e1" /></sentence><sentence text="5 [6" /><sentence text="3] vs 16" /><sentence text="5 [5" /><sentence text="5] ng/mL; 12" /><sentence text="8 [3" /><sentence text="0] vs 13" /><sentence text="3 [2" /><sentence text="8] h)" /><sentence text=" The oral clearance of rosuvastatin was not significantly affected by rifampicin pretreatment either (0"><entity charOffset="23-35" id="DDI-PubMed.18691987.s35.e0" text="rosuvastatin" /><entity charOffset="70-80" id="DDI-PubMed.18691987.s35.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.18691987.s35.e0" e2="DDI-PubMed.18691987.s35.e0" /><pair ddi="false" e1="DDI-PubMed.18691987.s35.e0" e2="DDI-PubMed.18691987.s35.e1" /></sentence><sentence text="4 [0" /><sentence text="3] vs 0" /><sentence text="3 [0" /><sentence text="2] L " /><sentence text=" h; P = 0" /><sentence text="072)" /><sentence text="" /><sentence text="The pharmacokinetics of rosuvastatin were not significantly changed by coadministration of rifampicin in this small group of healthy male volunteers"><entity charOffset="24-36" id="DDI-PubMed.18691987.s43.e0" text="rosuvastatin" /><entity charOffset="91-101" id="DDI-PubMed.18691987.s43.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.18691987.s43.e0" e2="DDI-PubMed.18691987.s43.e0" /><pair ddi="false" e1="DDI-PubMed.18691987.s43.e0" e2="DDI-PubMed.18691987.s43.e1" /></sentence><sentence text="" /></document>